Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways

被引:59
作者
Grogan, Patrick T. [1 ,2 ]
Sleder, Kristina D. [3 ]
Samadi, Abbas K. [3 ]
Zhang, Huaping [4 ]
Timmermann, Barbara N. [4 ]
Cohen, Mark S. [1 ,2 ,5 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA
[2] Univ Michigan Hosp & Hlth Syst, Dept Surg, Ann Arbor, MI 48109 USA
[3] Univ Kansas, Med Ctr, Dept Surg, Kansas City, KS 66160 USA
[4] Univ Kansas, Dept Med Chem, Sch Pharm, Lawrence, KS 66045 USA
[5] Univ Michigan Hosp & Hlth Syst, Sect Gen Surg, Taubman Ctr 2920K, SPC 5331, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
Withaferin A; Glioblastoma multiforme; Oxidative stress; Heat shock response; Akt/mTOR pathway; MAPK pathway; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; COMPOUND WITHAFERIN; MALIGNANT GLIOMAS; DOWN-REGULATION; MELANOMA-CELLS; APOPTOSIS; TARGET; AKT; TEMOZOLOMIDE;
D O I
10.1007/s10637-012-9888-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Withaferin A (WA), a steroidal lactone derived from the plant Vassobia breviflora, has been reported to have anti-proliferative, pro-apoptotic, and anti-angiogenic properties against cancer growth. In this study, we identified several key underlying mechanisms of anticancer action of WA in glioblastoma cells. WA was found to inhibit proliferation by inducing a dose-dependent G2/M cell cycle arrest and promoting cell death through both intrinsic and extrinsic apoptotic pathways. This was accompanied by an inhibitory shift in the Akt/mTOR signaling pathway which included diminished expression and/or phosphorylation of Akt, mTOR, p70 S6K, and p85 S6K with increased activation of AMPK alpha and the tumor suppressor tuberin/TSC2. Alterations in proteins of the MAPK pathway and cell surface receptors like EGFR, Her2/ErbB2, and c-Met were also observed. WA induced an N-acetyl-L-cysteine-repressible enhancement in cellular oxidative potential/stress with subsequent induction of a heat shock stress response primarily through HSP70, HSP32, and HSP27 upregulation and HSF1 downregulation. Taken together, we suggest that WA may represent a promising chemotherapeutic candidate in glioblastoma therapy warranting further translational evaluation.
引用
收藏
页码:545 / 557
页数:13
相关论文
共 54 条
[1]   2-Ethoxy-4,5-diphenyl-1,3-oxazine-6-one activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death [J].
Ansari, Niloufar ;
Khodagholi, Fariba ;
Amini, Mohsen .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 658 (2-3) :84-90
[2]   Role of Reactive Oxygen Intermediates in Cellular Responses to Dietary Cancer Chemoprevention Agents [J].
Antosiewicz, Jedrzej ;
Ziolkowski, Wieslaw ;
Kar, Siddhartha ;
Powolny, Anna A. ;
Singh, Shivendra V. .
PLANTA MEDICA, 2008, 74 (13) :1570-1579
[3]   Identification of Inhibitors of HSF1 Functional Activity by High-Content Target-Based Screening [J].
Au, Qingyan ;
Zhang, Yingjia ;
Barber, Jack R. ;
Ng, Shi Chung ;
Zhang, Bin .
JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (10) :1165-1175
[4]   Targeting ErbB Receptors in High-Grade Glioma [J].
Berezowska, Sabina ;
Schlegel, Juergen .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (23) :2468-2487
[5]  
Cabello CM, 2007, CURR OPIN INVEST DR, V8, P1022
[6]  
Chamberlain MC, 2010, EXPERT REV NEUROTHER, V10, P1537, DOI [10.1586/ern.10.32, 10.1586/ERN.10.32]
[7]  
Deneke SM, 2000, CURR TOP CELL REGUL, V36, P151
[8]  
Devi P. Uma, 2000, Indian Journal of Experimental Biology, V38, P432
[9]   Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding [J].
Evans, SM ;
Judy, KD ;
Dunphy, I ;
Jenkins, WT ;
Nelson, PT ;
Collins, R ;
Wileyto, EP ;
Jenkins, K ;
Hahn, SM ;
Stevens, CW ;
Judkins, AR ;
Phillips, P ;
Geoerger, B ;
Koch, CJ .
CANCER RESEARCH, 2004, 64 (05) :1886-1892
[10]   Hypoxia is important in the biology and aggression of human glial brain tumors [J].
Evans, SM ;
Judy, KD ;
Dunphy, I ;
Jenkins, WT ;
Hwang, WT ;
Nelson, PT ;
Lustig, RA ;
Jenkins, K ;
Magarelli, DP ;
Hahn, SM ;
Collins, RA ;
Grady, MS ;
Koch, CJ .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8177-8184